LOC729064 Inhibitors

LY294002 and Wortmannin are phosphoinositide 3-kinase (PI3K) inhibitors; their action can lead to the suppression of AKT phosphorylation and activity, which in turn can regulate proteins downstream of the PI3K/AKT pathway. Rapamycin is well-known for its inhibition of the mammalian target of rapamycin (mTOR), a key regulator of cell growth and protein synthesis, impacting the stability and function of proteins that are under the control of mTOR. PD98059, U0126, and SB203580 are inhibitors targeting the mitogen-activated protein kinase (MAPK) signaling cascade, which includes ERK, JNK, and p38 kinases. Inhibition of these kinases can result in altered transcriptional profiles and post-translational modifications, affecting protein expression and function. SP600125 specifically inhibits c-Jun N-terminal kinase (JNK), potentially affecting proteins that are regulated by the AP-1 transcription factor.

Dasatinib and PP2 inhibit Src family kinases, which are involved in a variety of cellular processes, including cell proliferation, survival, and differentiation. The inhibition of these kinases can lead to broad changes in cellular signaling and modify the activity of various proteins. ZM-447439 targets Aurora kinases, which play a critical role in cell division. Inhibition of Aurora kinases can disrupt normal mitotic events, impacting proteins that are crucial for cell cycle progression. Thapsigargin, by inhibiting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), leads to increased levels of cytosolic calcium, which can affect proteins sensitive to calcium signaling. Lastly, MG-132 is a proteasome inhibitor that can prevent the degradation of proteins, potentially leading to an accumulation of regulatory proteins within the cell.